Reference SummaryDiwan BA, Carcinogenesis 1997 Oct;18(10):2009-14
Title |
Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen. | ||||
Authors |
Diwan BA; Anderson LM; Ward JM | ||||
Journal |
Carcinogenesis | ||||
Volume |
18 | ||||
Issue |
10 | ||||
Year |
1997 | ||||
Pages |
2009-14 | ||||
Abstract |
Tamoxifen (TAM) is widely used as adjuvant breast cancer therapy after surgery and as a chemopreventive agent in women of child-bearing age. However, TAM therapy has been shown to result in an increased incidence of endometrial carcinoma in women. The present study was designed to investigate the effects of TAM (5 mg/kg and 7.5 mg/kg body wt) given i.g. to pregnant CD-1 mice (1x/day, days 12 through 18 of gestation) on their female offspring. Progressive proliferative hyperplasia of the oviduct was frequently seen in TAM-exposed offspring, reaching 100% incidence by 52 weeks in both treatment groups. These females also developed progressive proliferative uterine lesions, including moderate/severe cystic endometrial hyperplasia (34-50%) and polypoid adenomas (27-30%) between 53 and 78 weeks. Deciduomas (15%) occurred at young ages (12 and 24 weeks) while leiomyomas (14%), a malignant leiomyosarcoma, and ovarian granulosa cell tumors (14%), were found between 72 and 78 weeks. Our findings thus suggest a strong association between transplacental TAM and reproductive tract abnormalities in female CD-1 mice. | ||||
Links |
J:45982 – MGI References 9364013 – National Library of Medicine/PubMed |
||||
Strain Notes
|
|||||
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| CD-1 | Muscle - Smooth hyperplasia |
|
Uterus |
observed |
|
| CD-1 | Muscle - Smooth leiomyoma |
|
Uterus |
0 - 14 |
|
| CD-1 | Muscle - Smooth leiomyoma | Uterus |
0 |
||
| CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus |
0 - 4.5 |
|
| CD-1 | Muscle - Smooth leiomyosarcoma | Uterus |
0 |
||
| CD-1 | Ovary - Granulosa cell tumor |
|
Ovary - Granulosa cell |
0 - 14 |
|
| CD-1 | Ovary cyst |
|
Ovary |
0 - 86 |
|
| CD-1 | Ovary cyst | Ovary |
0 - 42 |
||
| CD-1 | Ovary tumor | Ovary |
0 |
||
| CD-1 | Oviduct hyperplasia |
|
Oviduct |
30 - 100 |
|
| CD-1 | Oviduct hyperplasia | Oviduct |
0 - 29 |
||
| CD-1 | Placenta - Decidua deciduoma |
|
Placenta - Decidua |
0 - 20 |
|
| CD-1 | Placenta - Decidua deciduoma | Placenta - Decidua |
0 |
||
| CD-1 | Uterus - Cervix tumor |
|
Uterus - Cervix |
0 |
|
| CD-1 | Uterus - Cervix tumor | Uterus - Cervix |
0 |
||
| CD-1 | Uterus - Endometrium carcinoma |
|
Uterus - Endometrium |
0 |
|
| CD-1 | Uterus - Endometrium carcinoma | Uterus - Endometrium |
0 |
||
| CD-1 | Uterus dysplasia |
|
Uterus |
observed |
|
| CD-1 | Uterus hyperplasia |
|
Uterus |
0 - 100 |
|
| CD-1 | Uterus hyperplasia | Uterus |
0 - 75 |
||
| CD-1 | Uterus metaplasia - squamous |
|
Uterus |
0 - 27 |
|
| CD-1 | Uterus metaplasia - squamous | Uterus |
0 |
||
| CD-1 | Uterus polyp - adenomatous |
|
Uterus |
0 - 30 |
|
| CD-1 | Uterus polyp - adenomatous | Uterus |
0 - 4.2 |
||
| CD-1 | Vagina tumor |
|
Vagina |
0 |
|
| CD-1 | Vagina tumor | Vagina |
0 |
||
| CD-1 | (Unspecified organ) tumor |
|
(Unspecified organ) |
0 |